CMPX vs TROW · $367.4M cap vs P/E 12, rev $7.09B
Compass Therapeutics Inc. (CMPX) versus T. Rowe Price Group Inc (TROW) — a side-by-side from cached financials, not a winner call.
Compass Therapeutics Inc. (CMPX) is a biotechnology company listed on US.
T. Rowe Price Group Inc (TROW) is a asset management company listed on NASDAQ.
CMPX does not have a complete income-statement cache yet.
Latest reported TROW revenue for 2024-12-31 was $7.09B. Net income was $2.14B. Revenue was up 9.8% from 2023-12-31 to 2024-12-31. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
CMPX currently screens at market cap $367.4M. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
Not investment advice. Open the CMPX and TROW stock pages for the full models.
Not investment advice.